Axe Trader Funded Axe Program with Unique Features

Axe Trader offers three types of programs, and one of them is Funded Axe Program. So, today, we will discuss the features and benefits of the Funded Axe Program and see if this is the one for you. Axe Trader Funded Axe program provides traders with advanced tools and opportunities to manage funded accounts ranging from $2,500 to $25,000. This program aims to streamline the trading process while maximizing profit potential through strategic account management.

Key Features of the Funded Axe Program 

• Account Size Options. Traders can select account sizes from $2,500 up to $25,000, catering to different trading preferences and account sizes.
• Increased Leverage. Traders can utilize up to 1:20 leverage, enhancing their trading capacity and potential returns.
• Profit Target. Traders have an initial 8% profit target, incentivizing focused trading strategies.
• Risk Management Guidelines. The program imposes strict risk management measures. This includes a 3% maximum daily loss and a 6% maximum cumulative loss cap.
• Payout Structure. Traders may receive their first payout within 8 calendar days from their initial trade upon achieving the 8% profit target. Subsequent withdrawals can be requested on a weekly basis.
• Profit Sharing Model. Traders are eligible to earn between 70% to 100% of their trading profits, based on performance metrics, offering a rewarding compensation scheme.
• Drawdown Options. Different account types offer varied drawdown rules. Regular Funded Axe accounts feature a locked drawdown. However, Aggressive Funded Axe accounts allow more flexibility in drawdown management.

The enhanced Funded Axe program shows Axe Trader’s commitment to empowering traders with robust tools and transparent opportunities for financial growth. This initiative aims to cater to both experienced traders and newcomers seeking to optimize their trading potential in dynamic market conditions.

So, use our Discount Code (FOREXPROPREVIEWS) for a 20% Discount or read the Review.